Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488098 | 1.00 | KDM4E (0.59) | KDM4EKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL6488102 | 1.00 | KDM4E (0.59) | KDM4EKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL8370165 | 0.82 | KMT2A (0.40) | KDM4EKMT2AMEN1 | |
| SCHEMBL19721184 | 0.81 | KDM4E (0.51) | KDM4EKMT2AMEN1ALDH1A1ACHE | |
| Noroxyhydrastinine SCHEMBL29745981 | 0.74 | KDM4E (1.00) | KDM4EACHECYP2D6 | |
| Noroxyhydrastinine SCHEMBL564339 | 0.74 | KDM4E (1.00) | KDM4EACHECYP2D6 | |
| SCHEMBL6476988 | 0.73 | KMT2A (0.68) | KDM4EKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL6476994 | 0.73 | KMT2A (0.68) | KDM4EKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL6476999 | 0.73 | KMT2A (0.68) | KDM4EKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL6485264 | 0.70 | PDPK1 (0.53) | KDM4EKMT2AMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930114-B2 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | PDE7B, PDE2A, PDE5A | KDM4E 714/4885KMT2A 1344/4885MEN1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.